Expand all sections

GSK525762

Extended indication NUT midline carcinoma (NMC) (een vorm van "squamous cell epithelial cancer")
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance GSK525762
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Oncology other
Extended indication NUT midline carcinoma (NMC) (een vorm van "squamous cell epithelial cancer")
Manufacturer GSK
Mechanism of action BET inhibitor
Route of administration Oral
Budgetting framework Intermural (MSZ)
Additional remarks BET family bromodomain inhibitor

Registration

Registration route Centralised (EMA)
Submission date 2020
Expected Registration 2021
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
References NCT01587703
Additional remarks gezien de vroege fase van klinische studies is het nog onduidelijk welke therapeutische waarde het middel mogelijk heeft en wat het behandelschema zal worden.

Expected patient volume per year

Additional remarks Betreft een ultra-zeldzame vorm van kanker, zeer klein aantal patiënten verwacht die hiervoor in aanmerking gaan komen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Lopende studies o.a. naar het effect bij Solide tumoren
References clinicaltrials.gov

Other information

There is currently no futher information available.